Due to the lack of efficacy seen in single-agent ICI in many gastrointestinal tumors so far, we anticipate that combination therapy such as co-blockade of PD-1 and IL-10 will offer a higher chance of success15. This evidence concerns the gene PDCD1 and digestive system neoplasm.